Piramal Group
Piramal Group Group Stocks
Check out the complete list of shares/stocks of Piramal Group listed on NSE & BSE.
| Company Name | ₹ LTP (Change %) | Volume | Market Cap | 52 Week High | 52 Week Low |
|---|
🧺 Invest in the entire group with one basket order
The Piramal Group is a major Indian corporate name. It has evolved through strategic acquisitions and restructuring guided by Ajay Piramal and senior leadership. Today, the group manages assets worth billions and continues to influence the NBFC (Non-Banking Financial Company) and healthcare sectors. The group maintains operations across global markets and regions. It employs thousands of professionals worldwide. Its diversified portfolio supports balanced revenue streams.
In the Indian stock market, Piramal stocks are often seen as high-potential assets. This is due to the group’s recent strategic demergers between its pharma and finance businesses, allowing both to grow with focused strategies. Investors monitor these stocks closely for their dividend histories and strategic acquisitions in the stressed-asset space. This blog highlights Piramal Group stocks and business operations.
About Piramal Group of Companies
The Piramal Group is a well-established multinational Indian business conglomerate. It was established in 1984 by Ajay Piramal. The business began as a textile manufacturing company. Over the decades, it expanded into high-growth sectors worldwide.
Its major focus areas include lending, pharmaceuticals, and real estate. It also works in healthcare and contract manufacturing services. These sectors offer steady and scalable opportunities. The group operates mainly in financial services and pharmaceuticals, primarily through two listed companies: Piramal Enterprises Ltd (PEL) and Piramal Pharma Ltd (PPL).
Piramal Enterprises has transitioned into a diversified non-banking financial company (NBFC) following its major demerger. The company focuses on retail lending, housing finance, and asset management. It has investments and assets worth around ~$10 billion, with retail loans forming a growing share of the portfolio.
On the other hand, Piramal Pharma Limited (PPL) operates the healthcare business. It has around 17 global development and manufacturing facilities. It includes a robust Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), and a complex hospital generics business.
Today, Piramal Group operates in more than 30 countries. Its core areas include pharma, finance, and real estate. The group employs over 18,000 professionals and serves customers across 100+ international markets.
Moving ahead, the group combines stable sectors with growth-oriented businesses. Strategic restructuring has improved operational focus. It remains relevant for long-term portfolio consideration.
Frequently Asked Questions
You can purchase these shares through any SEBI-registered stockbroker in India. First, open a Demat and trading account. Search for “PEL” for financial services or “PPLPHARMA” for the pharmaceutical entity. Place a buy order at the current market price or a limit price.
Piramal Enterprises (PEL) is often tracked for its shift towards retail lending. Its long-term growth depends on how well this segment scales and improves margins. Investors usually monitor asset quality, loan growth, and overall profitability trends rather than short-term price movements. Piramal Pharma is also preferred by investors looking for exposure to global healthcare and CDMO recovery. Long-term investors should monitor the company’s return on assets (ROA). However, consulting a financial adviser before committing large amounts of capital is advisable.
Ajay Piramal is the chairman and primary promoter of the group. The promoter group holds a significant portion of the total equity shares. Institutional investors and the public own the remaining portion of the stocks. High promoter holding often indicates strong confidence in the company’s future. The leadership remains focused on delivering sustainable value to all retail shareholders.
Piramal Enterprises Limited remains the largest entity in terms of market capitalisation. It manages a large and diversified loan book across segments. The company’s operations in retail finance drive its valuation in the market. It maintains a widespread network across urban and rural regions in India, allowing it to compete effectively with other major NBFCs.
The group holds various stakes across its subsidiaries and some minority holdings in other companies. Piramal Enterprises operates as the holding entity for its financial businesses. The total number of outstanding equity shares for PEL is approximately 22.5 crore. Out of this, promoters own nearly 10.46 crore shares, which is about 46% of the company’s equity. Foreign investors hold about 15% of the company. Retail investors and others contribute a notable shareholding portion.
There are two main listed stocks in the Piramal Group: Piramal Enterprises Limited (PEL), which focuses on finance, and Piramal Pharma Limited (PPL), which focuses on healthcare. PEL is known for its dividend yield and retail lending focus. PPL is recognised for its global CDMO services and consumer products. Both stocks are actively traded on the NSE and BSE. Investors track these to understand the group’s overall performance.
As a financial services-heavy group, Piramal Enterprises carries significant debt, which is standard for the NBFC sector. The total debt reported as of the latest financial cycle was approximately ₹708.56 billion. However, this is largely working capital used for lending. The group is actively reducing its high-cost wholesale debt to improve margins.
Investors tracking Piramal may also monitor other major Indian conglomerates. The Tata Group has a presence across multiple sectors. Reliance Industries is another essential group for overall market sentiment. In the NBFC space, Bajaj Finance and Shriram Finance are direct competitors. Comparing these groups helps investors understand broader economic trends.
Piramal Enterprises Limited consistently generates the highest revenue within the group. It recorded ₹276 crore net profit in the latest quarterly results. The pharmaceutical division is also showing an upward trend in global profitability. The CDMO business is a significant contributor to the group’s net profit. Improved margins in retail lending have further strengthened overall financial performance.